While TFE3 IHC has been considered a specific diagnostic protein assessment for SPN [58, 59], recent studies have reported TFE3 expression in other pancreatic tumors, with positivity rates of up to 14.3% in PDAC and 23.5% in PanNET, significantly limiting its diagnostic specificity. Here, TFE3 is linked to pancreatic neoplasm.